Empire Financial Management Company LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Empire Financial Management Company LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the first quarter, HoldingsChannel.com reports. The firm bought 1,826 shares of the biopharmaceutical company’s stock, valued at approximately $1,411,000.

Several other institutional investors have also recently bought and sold shares of REGN. Lockheed Martin Investment Management Co. bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $2,702,000. Asio Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $3,422,000. Robeco Institutional Asset Management B.V. lifted its stake in shares of Regeneron Pharmaceuticals by 116.6% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock valued at $202,114,000 after acquiring an additional 140,966 shares during the last quarter. National Pension Service lifted its stake in shares of Regeneron Pharmaceuticals by 29.8% in the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after acquiring an additional 82,853 shares during the last quarter. Finally, AE Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 36.7% during the 4th quarter. AE Wealth Management LLC now owns 5,474 shares of the biopharmaceutical company’s stock valued at $4,226,000 after acquiring an additional 1,470 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts expect Regeneron’s second-quarter performance to be supported by continued demand for Dupixent, Eylea HD and Libtayo. Investors will also watch for updates on share repurchases, earnings guidance and the broader development pipeline. Will REGN’s Q2 Earnings Get a Boost From Dupixent and Eylea HD?
• Neutral Sentiment: Multiple law firms announced or promoted securities class actions against Regeneron and certain executives. The cases generally cover investors who purchased shares from August 1, 2025, through May 15, 2026, with September 14, 2026, cited as the lead-plaintiff deadline. The notices primarily repeat earlier allegations and are not new operating developments. Faruqi & Faruqi Equity Action Notice
• Negative Sentiment: The legal actions stem from disclosures about Regeneron’s Phase 3 Fianlimab-Libtayo melanoma trial. Reports allege that investors were not fully informed as the trial moved from delayed event accruals to a protocol amendment and ultimately failed to meet its primary endpoint. The trial failure reportedly contributed to an approximately 9%–10% share-price decline and erased about $11 billion in market value, raising concerns about pipeline execution and potential litigation costs. Hagens Berman Regeneron Trial Alert

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on REGN shares. HSBC reduced their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Barclays cut their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Finally, Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $787.88.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $695.18 on Wednesday. The stock has a market cap of $73.49 billion, a price-to-earnings ratio of 16.94, a P/E/G ratio of 1.48 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $821.11. The company’s fifty day moving average is $637.83 and its 200 day moving average is $712.50. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same period last year, the company earned $8.22 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.